News Column

Therapeutic Proteins International Releases Authoritative Abstract on Biosimilars at BIO Conference

July 2, 2014



By a News Reporter-Staff News Editor at Biotech Week -- "Because BIO conference is focused on the biopharmaceutical industry, this forum presents a great opportunity to begin to educate the marketplace with informative content on biosimilars that is relevant and timely," said Dr. Niazi. "As the industry continues to experience tremendous regulatory change, one thing is certain, there needs to be a deeper understanding of the benefits of biosimilars within the healthcare industry."

As an expert in an industry that is undergoing tremendous regulatory change, Niazi brings a credible and unique perspective that is highly applicable to the industry. In an era of accelerating transformation and complexity, Niazi has an exceptional understanding of the needs of the industry and how biosimilars will benefit everyone from providers to patients (see also Therapeutic Proteins International).

By 2015, sales of biosimilars are expected to reach between US $1.9-2.6 billion, up from US $378 million for the year to the first half of 2011 according to the IMS report, "Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape,". The Biosimilars market could be the single fastest-growing biologics sector in the next five years. About Dr. Sarfaraz Niazi Sarfaraz K. Niazi, Ph.D., is an architect of and a leading authority on today's biologics drug industry. As Founder, Chairman and CEO of Therapeutic Proteins International, a developer and manufacturer of biosimilar drugs, he's set out to revolutionize the way drugs are made to enable access to high quality life altering drugs at an affordable cost to all those that need them.

Before founding Therapeutic Proteins International, Niazi was director, technical affairs in Abbott Laboratories International Division and became tenured at Abbott as their Volwiler Fellow. He began his career teaching at the University of Illinois, College of Pharmacy where he was a tenured professor. About Therapeutic Proteins International (TPI) Therapeutic Proteins International, LLC (TPI) is a fully integrated manufacturer of biosimilar recombinant protein products. Located in Chicago, Illinois, TPI is exclusively focused on developing and manufacturing biosimilar products with nine currently in its development pipeline. For additional information go to www.theraproteins.com or call 312.620.1500. Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140619005050/en/

Keywords for this news article include: Biotechnology, Peptides, Amino Acids, Biologicals, Therapeutic Proteins International.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters